Politics
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
€2.2 million Eurostars Project
AdjuTec Pharma has been awarded a €2.2 million Eurostars grant together with international partners. The funding will support the development of new drug combinations for patients suffering from severe lung infections caused by multidrug-resistant bacteria.
Lung infections are increasingly caused by bacteria that no longer respond to modern antibiotics. In this programme, AdjuTec Pharma’s novel resistance breaker APC148 will be tested in combination with different antibiotics.
Published
Aug 26, 2025
Category
Start-up
AdjuTec Pharma has announced the signing of a consortium agreement following encouraging feedback from the Eurostars evaluators.
“The Eurostars project further reinforces our commitment to bring to market best-in-class antibiotic solutions to meet the unmet needs of patients with severe lung infections. In collaboration with our partners, this development will strategically expand the commercial applicability and clinical utility of AdjuTec Pharma’s groundbreaking antibiotic technology platform,” said Jethro Holter, CEO of AdjuTec Pharma.
The start-up company is a part of Oslo Cancer Cluster Incubator. It is developing antibiotic resistance breakers.
A strong consortium
AdjuTec Pharma applied for Eurostars funding on behalf of a consortium of four SME partners. These are:
- Vivexia (France), a leading laboratory that will perform in vivo microbiology testing.
- PureIMS (The Netherlands), which will develop and investigate inhalation characteristics of the formulation.
- CTC (Sweden), a clinical CRO that will assess lung availability of test compounds in healthy volunteers.
Together, the consortium will identify the most efficient drug combination of selected multidrug-resistant bacterial strains and secure adequate drug dosing to the lungs, treating patients with severe lung infections caused by multidrug-resistant bacteria.
New drug combinations
The project activities will span microbiology, toxicology, drug formulation, and clinical testing in healthy volunteers. AdjuTec Pharma will coordinate the consortium and conduct in vitro microbiology screening and toxicology testing.
“The signing of the Eurostars consortium agreement is exciting news for AdjuTec Pharma, as it will expand our technology into a new patient population with severe lung infection. Together with our partners, we will investigate new drug combinations and formulations to broaden the commercial potential of partner technologies and competences,” commented Bjørn Klem, COO and project coordinator, in Adjutec Pharma's press release.
The Eurostars project is scheduled to run for three years, beginning at the end of 2025.
For further background, read more about antimicrobial resistance (AMR) on the WHO-fact page.
